AI for Dry AMD

Book free trial to see how AI can detect Dry AMD and 70+ other pathologies/biomarkers

Book Intro

Altris AI is an FDA-cleared platform for OCT scan analysis that detects the earliest pathological signs of Dry AMD (dAMD), such as drusen, pigmentary abnormalities, and other subclinical biomarkers of this pathology. It provides:

Precise and swift analysis with volumetric and area measurements of all dAMD biomarkers.

Drusen measurements: type, volume, area, size.

Progression analysis: automated longitudinal comparison across multiple examinations.

Platform overview

Only practical features for eye care specialists and clinical research

GDPR compliant (all data is encrypted), CE-certified, and FDA- cleared (510k).

William C. Fruchtman, Optometry Owner

I was really excited to find Altris AI to bolster my skills identifying certain macular diseases. It's a great program and has guided me in the diagnosis of complex cases.

3 Oct, 2024

Scott Sedlacek Optometry Owner

Altris AI identified and described pathology that I could not. Early detection changes the treatment from doing nothing to something. Also, Altris AI described something that I thought was worse than it was. Saved me from over-referring. Patients love to see the color-coded images which help as an educational tool and get buy-in on the treatment plan which helps compliance.

1 Feb, 2024

Richard Clare Optometry Owner

We are adding a new OCT to one of our practices and may benefit from some extra support with AI to speed up the interpretation of results and assist the busy Optometry team.

Dec 7, 2023

Make informed decisions based on objective insights with AI OCT for dAMD.

Altris AI offers standardized and reproducible examination with accurate volumetric and area measurements down to micrometers.

Add OCT examinations from different visits

Identify Dry AMD biomarkers with color-coding

Explore the area and volume of biomarkers

Track how dAMD changes over time in Progression module

How Altris AI works?

And what's the value of using Artificial intelligence for Dry AMD (dAMD)

Altris AI is a web platform created by retina experts for all eye care specialists and clinicians.

We’ve collected millions of OCT scans, and our team graphically labeled thousands of them to create the Altris AI system that can:

Detect 70+ pathologies and biomarkers, including early dAMD biomarkers.

Measure and track pathological changes across multiple examinations.

Formats

DICOM format will help you to extract maximum information. However, the system works with all data formats, such as jpg, and png

OCT equipment

Altris AI is vendor-neutral. We work with all the OCT equipment producers

OCT reports

We create comprehensible OCT reports for patients and doctors

For clinical research

What you get with Altris AI:

Accelerate ophthalmic drug trial with AI
Detect Dry AMD, nAMD, Geographic atrophy and their biomarkers ( +70 retinal pathologies and biomarkers)
Track the progression of biomarkers to assess drug efficiency
Enroll the right patients based on fast biomarkers detection
Reduce costs associated with manual scan review with automated analysis

For eye care

We support you through the whole way

14 Days of Free Trial to see the value
Support during the whole trial period
Early glaucoma assessment module access
CE-certified, GDPR, HIPAA compliant, FDA clearance
Integration support with any EHR, EMR system.
Cloud data storage/on premises possible
Access to the whole functional during trial